Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=pyrilutamide,retatrutide,cagrilintide

Side-by-side comparison of Pyrilutamide, Retatrutide, Cagrilintide
PyrilutamideRetatrutideCagrilintide
Identity
ClassInvestigational topical nonsteroidal androgen-receptor antagonistInvestigational triple agonist of GIP, GLP-1 and glucagon receptorsInvestigational long-acting acylated amylin analogue
Also listed asKX-826, KX826, Pyrilutamide topicalLY3437943, LY-3437943Not recorded
Molecular formulaNot recordedNot recordedC194H312N54O59S2
Molecular weightNot recorded4731.33 g/mol (average mass, widely cited for the free base)4409 g/mol
CASNot recorded2381089-83-21415456-99-3
PubChem CIDNot recordedNot recorded171397054
Sequence lengthNot recordedNot recordedDescribed structurally, not as a residue list
Data caveatNone recordedPubChem’s retatrutide record states a CID is not available as a discrete structure. Full caveatNone recorded
United States regulatory status
StatusInvestigationalInvestigationalInvestigational
FDA applicationNone recordedNone recordedNone recorded
CompoundingNo FDA compounding entry recordedNo FDA compounding entry recordedNo FDA compounding entry recorded
WADANot named in this recordNot named in this recordNot named in this record
Research profile
Research purposeTopical androgen-receptor blockadeTriple-agonist metabolic researchNo plain-English profile recorded
Proposed mechanismA nonsteroidal androgen-receptor antagonist applied to the scalp, intended to reduce androgen signalling in follicle cells. The clinical advantage over existing treatments is not established.Proposed triple agonism: GLP-1 and GIP effects on appetite and insulin, plus glucagon-receptor signalling in the liver and energy expenditure. The net clinical contribution of each arm is still being studied.No plain-English profile recorded
Human evidencePhase 2 trials in men and women and a Phase 3 trial in Chinese men are registered; the Phase 2 studies are listed as completed. No approved product.A published 48-week Phase 2 trial in 338 adults, plus Phase 3 trials registered and sponsor topline disclosures. No approved product exists.No plain-English profile recorded
Evidence tierPhase 3 trials registered or reportedPhase 3 trials registered or reportedNo plain-English profile recorded
Known safety concerns
  • Topical androgen-receptor blockade may still produce systemic effects; the trials are designed to measure this.
  • Phase 3 safety data are not available here as a peer-reviewed report.
  • Long-term safety is unknown.
  • Gastrointestinal adverse effects were reported in the Phase 2 trial.
  • Resting heart rate increased transiently in the Phase 2 trial.
  • The full Phase 3 safety database and any regulatory review are not public as an approved label.
No plain-English profile recorded
Evidence gaps
  • Peer-reviewed Phase 3 efficacy and safety results.
  • Whether topical delivery avoids meaningful systemic androgen blockade.
  • Durability and any regulatory decision.
  • Peer-reviewed Phase 3 results, including full adverse-event tables.
  • Long-term cardiovascular and lean-mass outcomes.
  • Any regulatory decision.
No plain-English profile recorded
Head-to-head evidenceNo published head-to-head trial against finasteride or minoxidil.No published head-to-head trial against semaglutide or tirzepatide. Cross-trial comparisons are not head-to-head evidence.No plain-English profile recorded
Named pathwaysAndrogen receptor · DHT signalling · Follicular miniaturisationGIP receptor · GLP-1 receptor · Glucagon receptor · Hepatic lipid oxidation · Energy expenditureNo plain-English profile recorded
Evidence on file
Records
Human-interventional records220
Human-observational records000
Animal records000
In-vitro records000
Reviews000
Regulatory documents000
Earliest indexed20222023Not recorded
Latest indexed20242026Not recorded

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.